Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Another Blow for Genzyme
- Zacks.com submits: Genzyme Corp. GENZ suffered yet another setback yesterday when Protalix BioTherapeutics Inc. announced that the US Food and Drug Administration (FDA) has approved the treatment protocol for its experimental drug for Gaucher disease. This means that the drug, prGCD, will be available for the treatment of...
- External links 2009-08-18
- Agilent Q3: Turning the Corner
- Zacks.com submits: Agilent Technologies’ ([[A]] - Snapshot Report) third quarter earnings beat the consensus by 9 cents. Revenue of $1.06 billion also beat by 3.9%. Revenue declined 3.1% sequentially and 26.8% year over year. Electronic Measurement (EM) generated $524 million, down 6.1% sequentially and 35.6% year over...
- External links 2009-08-18
- Valeant?s Pain Drug Disappoints
- Zacks.com submits: Yesterday, Valeant Pharmaceuticals International VRX announced the failure of its drug candidate, retigabine, in a mid-stage study. The trial evaluated retigabine for pain associated with postherpetic neuralgia (PHN), which is common in shingles. The company’s shares closed down 8.5% at $ 24.85. Retigabine was tested in...
- External links 2009-08-25
- Genzyme?s Problems Continue
- Zacks.com submits: Genzyme Corp. GENZ suffered a setback last week when Shire Plc. SHPGY announced positive phase III results on velaglucerase alfa, an enzyme replacement therapy, which is being developed for the treatment of Gaucher disease. Shire has initiated the process of submitting its New Drug...
- External links 2009-08-09
- Amicus Therapeutics: Amigal Drug Shows Promise
- Zacks.com submits: Amicus Therapeutics FOLD began registration for phase III trial of its investigational drug Amigal for the treatment of Fabry disease and expects to begin the dosing of subjects in the second half of this year. Along with the US FDA, the company has already decided on...
- External links 2009-07-07
- Isis Generating Impressive Oncology, Diabetes Data
- Zacks.com submits: By Jason Napodano, CFA At perhaps the two biggest industry trade conferences of the year, the American Society of Clinical Oncology (ASCO) and the American Diabetes Association (ADA), Isis Pharmaceuticals ISIS and/or its partners presented encouraging pre-clinical and early-stage clinical data showing the potential power of...
- External links 2009-06-24
- Monogram's Acquisition of LabCorp: What Does It Mean for the Molecular Diagnostics Industry?
- Zacks.com submits: By Grant Zeng, CFA Early yesterday morning, Laboratory Corporation of America® Holdings, or LabCorp LH and Monogram Biosciences, Inc. MGRM announced that they have entered into a definitive agreement and plan of merger under which LabCorp will acquire all of the outstanding shares of Monogram in...
- External links 2009-06-24
- Luminex: Expect Strong Growth in 2009
- Zacks.com submits: By Brian Marckx Luminex Corp. LMNX posted revenue of $104.5 million in 2008, marking growth of 39% from 2007. Technology segment sales increased 34% to $83.6 million, while Assay segment sales grew 66% to $20.9 million. Through the first quarter 2009, Technology segment sales grew 13%...
- External links 2009-06-29
- Promising Year Ahead for Optimer Pharma
- Zacks.com submits: Optimer Pharmaceuticals OPTR recently announced results from the phase III clinical study of fidaxomicin in patients with Clostridium difficile-associated diarrhea (CDAD) at the Digestive Disease Week 2009 conference in Chicago. The data presented dealt with patient risk factors related to recurrence of CDAD following...
- External links 2009-06-29
- Genomic Health Inc. Needs Label Expansion
- Zacks.com submits: By Grant Zeng, CFA Oncotype DX for Breast Cancer is Growth EngineGenomic Health Inc. GHDX is an oncology-based biotech company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The company’s first...
- External links 2009-06-26
- Anadys Pharmaceuticals: Earnings Report Is a Non-Event
- Zacks.com submits: San Diego-based biopharmaceutical company Anadys Pharmaceuticals Inc. ANDS is expected to release its second-quarter earnings on July 30, 2009. We expect the company to post a net loss of $6.9 million. Basic and diluted net loss per common share is expected to be $0.22. The company...
- External links 2009-07-23
- Syneron to Acquire Primaeva
- Zacks.com submits: Syneron Medical Ltd. ELOS is set to acquire Primaeva Medical, Inc., an aesthetic technology firm based in Pleasanton, CA. The acquisition is expected to close before the end of 2009. Per the agreement, Syneron will acquire Primaeva for $7 million in cash and up to $23...
- External links 2009-10-19
- Amgen Q3: Beats Nicely, Raises Guidance
- Zacks.com submits: Amgen AMGN reported third quarter earnings per share of $1.47, well above the Zacks Consensus Estimate of $1.26 and 21% above the year-ago earnings of $1.21. Cost cuts and a lower tax rate helped boost the top-line despite a 2% decline in total revenues, which came...
- External links 2009-10-22
- Gilead Closer to FDA Approval for CF Drug
- Zacks.com submits: Gilead Sciences, Inc GILD received a positive opinion from the Anti-Infective Drugs Advisory Committee of the US Food and Drug Administration (FDA). Gilead is seeking FDA approval for inhalable aztreonam for the treatment of lung infection caused by Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic...
- External links 2009-12-12
- Good News for Dynavax HBV Vaccine
- Zacks.com submits: Dynavax Technologies Corp. DVAX announced recently that it has received approval from the European Union to make part of its hepatitis B vaccine (HBV) Heplisav at a German factory. The EU approval permits Dynavax to commercially produce hepatitis B surface antigen, a key component of Heplisav...
- External links 2009-12-12
- Cepheid Narrows Loss in Q3
- Zacks.com submits: Cepheid’s CPHD third quarter net loss per share of 6 cents was much better than the Zacks Consensus Estimate of 12 cents as well as a loss of 12 cents reported in the third quarter of 2009. Although revenues for the quarter came down by 7%...
- External links 2009-11-30
- FDA Approves Gen-Probe Assay
- Zacks.com submits: Recently, Gen-Probe Inc. GPRO announced that it has received the green light from the U.S. Food and Drug Administration (FDA) to market ProParaflu Plus assay. The assay, developed by Prodesse, a wholly-owned subsidiary of Gen-Probe, is a molecular test for detecting and differentiating parainfluenza 1, 2,...
- External links 2009-11-26
- Genzyme's MS Drug Shows Promise
- Zacks.com submits: On Friday, Genzyme Corp. GENZ presented encouraging four-year follow-up phase II data on alemtuzumab, which is being developed for the treatment of multiple sclerosis (MS). Results showed durable reductions in relapse rate and sustained accumulation of disability even three years after patients received their last course...
- External links 2009-09-17
- Forest Labs Presents Encouraging Pneumonia Drug Data
- Zacks.com submits: We are pleased to hear that Forest Laboratories FRX presented encouraging data from its phase III trial of ceftaroline for the treatment of community-acquired pneumonia (CAP) in hospitalized patients. The company presented new data from two multicenter studies – FOCUS 1 and FOCUS 2 – at...
- External links 2009-09-15
- Auxilium Inches Toward FDA Approval for Xiaflex
- Zacks.com submits: Auxilium Pharma AUXL is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major boost in the form of a favorable...
- External links 2009-10-14
- << Previous
- page 1 of 3
- Next >>
Presented by American Express